New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:34 EDTNBYNovaBay announces completion of enrollment in Phase 2 BAYnovation trial
NovaBay announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. The trial is investigating NovaBay’s Auriclosene -- NVC-422 -- Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious, potentially sight-impairing form of “pink eye”. This condition affects millions of people globally and there is currently no approved treatment available anywhere in the world. NovaBay expects to report results from its trial in mid-2014. BAYnovation is a multi-centered, randomized clinical study that has enrolled patients with adenoviral conjunctivitis in the United States, India, Sri Lanka, and Brazil. Patients were enrolled into the study by 54 clinical investigators, including 18 in the US, 19 in India, 6 in Sri Lanka and 11 in Brazil. BAYnovation was designed to evaluate the efficacy of NovaBay’s Auriclosene Ophthalmic Solution in the treatment of adenoviral infection, specifically clearing the associated red eye and reducing lingering effects left by the infection.
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
06:15 EDTNBYNovaBay files to sell 25.7M shares of common stock for holders
Subscribe for More Information
March 26, 2015
09:15 EDTNBYNovaBay reports Q4 EPS (9c), one estimate (7c)
Reports Q4 revenue $385,000, one estimate $60,000. "Avenova sales in February were double January sales, and sales in March are well outpacing those in February. We are making progress on the second component of our plan of introducing innovative eye care products to leverage our salesforce. We expect to introduce a cream version of Avenova for overnight use and are developing additional products that we plan to launch in the coming 12 to 18 months.," said the company. Cash, cash equivalents and short-term investments were $5.4M as of December 31.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use